Treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA.
For this indication, competent medicine agencies globally authorize below treatments:
For: Adults (18-64) Elders (65+)
Subcutaneous, 0.7 milligrams per kilogram of body weight, one dose, over the duration of 1 week. Afterwards, subcutaneous, 1 milligrams per kilogram of body weight, once weekly, over the duration of 11 weeks.
An initial single dose of 0.7 mg/kg body weight is given followed by weekly injections of 1.0 mg/kg body weight (maximum single dose should not exceed a total of 200 mg). The volume to be injected should be calculated as follows:
|Dose||Volume to be injected per 10 kg body weight|
|Single initial dose: 0.7 mg/kg||0.07 ml|
|Subsequent doses: 1 mg/kg||0.1 ml|
The duration of therapy is 12 weeks. Therapy may be continued only in patients who responded to treatment (PGA good or better).
Injection sites should be rotated.